Trial · NCT05201404
Namodenoson in the Treatment of Advanced Hepatocellular Carcinoma in Patients With Child-Pugh Class B7 Cirrhosis
NCT05201404, Phase 3, Recruiting, Can-Fite BioPharma
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Namodenoson in the Treatment of Advanced Hepatocellular Carcinoma in Patients With Child-Pugh Class B7 Cirrhosis. Trials, record NCT05201404. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT05201404
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Namodenoson in the Treatment of Advanced Hepatocellular Carcinoma in Patients With Child-Pugh Class B7 Cirrhosis
- NCT number
- NCT05201404
- Status
- Recruiting
- Phases
- Phase 3
- Enrollment
- 471 participants, estimated
- Lead sponsor
- Can-Fite BioPharma
- Conditions
- Hepatocellular Carcinoma, Cirrhosis
- Interventions
- Namodenoson, Placebo
- First posted
- 2022-01-21
- Last updated
- 2025-04-29
Source ClinicalTrials.gov
Registered outcomes9
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Overall Survival (OS) | From the time of randomization until the date of death from any cause, assessed up to 60 months | Median duration of survival |
| Secondary | Progression-Free Survival (PFS) | From the time of randomization until the date of disease progression or death from any cause, assessed up to 60 months | Median time to disease progression using RECIST and modified RECIST criteria |
| Secondary | Objective Response Rate (ORR) | Through study completion, with a median of 9 months | Proportion of patients who experience Objective Response (OR) using RECIST and modified RECIST criteria |
| Secondary | Incidence and nature of treatment-emergent adverse events | Through study completion, with a median of 9 months | Incidence and nature of treatment-emergent adverse events as assessed using National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE v5) |
| Secondary | Pharmacokinetics (PK) of namodenoson in this population | 29 days | Plasma concentration of namodenoson |
| Other | Duration Of Response (DOR) | Through study completion, with median of 9 months | Time from first response (CR or PR) to progression or death, whichever occurs first |
| Other | Disease Control Rate (DCR) | Through study completion, with median of 9 months | Proportion of patients who experience OR as well as those who experience Stable Disease (SD) for at least four treatment cycles, ie, four months |
| Other | Quality of Life (QOL) using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core-30 (EORTC QLQ-C30) | Through study completion, with a median of 9 months | Assess QOL in this population using the EORTC QLQ-C30, a 30-item questionnaire. Each question is measured in a range in score from 0 to 100. A high scale score represents a higher response level. |
| Other | Quality of Life (QOL), using the hepatocellular carcinoma- (HCC-) specific module of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Hepatocellular Carcinoma 18-question Module (EORTC QLQ-HCC18) | Through study completion, with a median of 9 months | Assess QOL in this population using the HCC-specific module of the EORTC QLQ-HCC18, an 18-item questionnaire. Each question is measured in a range in score from 0 to 100. A high scale score represents a higher response level. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers4
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT05201404
GET https://conductscience.org/api/trials/v1/NCT05201404/registered